With expert's help, Talon wins ODAC support for Marqibo
This article was originally published in Scrip
Executive Summary
Talon Therapeutics came out a winner at the 21 March meeting of the US FDA's Oncologic Drugs Advisory Committee (ODAC) after putting the reins of the firm's experimental drug Marqibo (vincristine sulfate liposomes injection) into the skillful hands of leukaemia expert Dr Susan O'Brien, who masterfully rode that dark horse all the way to the finish line.